Evidence map›Paper›PMID 39150046›Full record

Observational studyThe British journal of surgery2024

Sex-related differences in oncological surgery and postoperative outcomes: comprehensive, nationwide study in France.

Floriane Jochum, Anne-Sophie Hamy, Paul Gougis, Élise Dumas, Beatriz Grandal, Mathilde Sauzey, Enora Laas, Jean-Guillaume Feron, Virginie Fourchotte, Thomas Gaillard and 9 more

Abstract readObservational Study
In one paragraph

Observational study in The British journal of surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Floriane JochumResidual Tumour and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.ORCID 0000-0001-5009-3936
Anne-Sophie HamyResidual Tumour and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.ORCID 0000-0003-4430-3022
Paul GougisResidual Tumour and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.
Élise DumasResidual Tumour and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.
Beatriz GrandalResidual Tumour and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.
Mathilde SauzeyResidual Tumour and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.
Enora LaasDepartment of Breast and Gynaecological Surgery, Institut Curie, Paris, Université Paris Cité, Paris, France.
Jean-Guillaume FeronDepartment of Breast and Gynaecological Surgery, Institut Curie, Paris, Université Paris Cité, Paris, France.
Virginie FourchotteDepartment of Breast and Gynaecological Surgery, Institut Curie, Paris, Université Paris Cité, Paris, France.
Thomas GaillardDepartment of Breast and Gynaecological Surgery, Institut Curie, Paris, Université Paris Cité, Paris, France.
Noemie GirardDepartment of Breast and Gynaecological Surgery, Institut Curie, Paris, Université Paris Cité, Paris, France.
Lea PaulyDepartment of Breast and Gynaecological Surgery, Institut Curie, Paris, Université Paris Cité, Paris, France.
Elodie GauroyDepartment of Breast and Gynaecological Surgery, Institut Curie, Paris, Université Paris Cité, Paris, France.
Lauren DarriguesDepartment of Breast and Gynaecological Surgery, Institut Curie, Paris, Université Paris Cité, Paris, France.
Judicael HottonDepartment of Surgical Oncology, Institut Godinot, Reims, France.
Lise LecointreDepartment of Gynaecology, Strasbourg University Hospital, Strasbourg, France.
Fabien ReyalResidual Tumour and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, Paris, France.ORCID 0000-0002-2318-3589
Fabrice LecuruDepartment of Breast and Gynaecological Surgery, Institut Curie, Paris, Université Paris Cité, Paris, France.
Cherif AkladiosDepartment of Gynaecology, Strasbourg University Hospital, Strasbourg, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe main objective of this study was to undertake an exhaustive investigation of sex-related differences in cancer surgery.

methodsThis observational study used data from the French national health insurance system database covering 98.8% of the population. Patients diagnosed with non-sex-specific solid invasive cancers between January 2018 and December 2019 were included. The main outcomes were likelihood of undergoing cancer surgery, type of oncological surgery performed, and associated 30-, 60-, and 90-day postoperative reoperation and mortality rates, by sex.

resultsFor the 367 887 patients included, women were 44% more likely than men to undergo cancer surgery (OR 1.44, 95% c.i. 1.31 to 1.59; P < 0.001). However, the likelihood of surgery decreased with advancing age (OR 0.98, 0.98 to 0.98; P < 0.001), and with increasing number of co-morbid conditions (OR 0.95, 0.95 to 0.96; P < 0.001), especially in women. Men had higher 90-day reoperation (21.2 versus 18.8%; P < 0.001) and mortality (1.2 versus 0.9%; P < 0.001) rates than women, overall, and for most cancer types, with the exception of bladder cancer, for which the 90-day mortality rate was higher among women (1.8 versus 1.4%; P < 0.001). After adjustment for age, number of co-morbid conditions, and surgical procedure, 90-day mortality remained higher in men (OR 1.16, 1.07 to 1.26; P < 0.001), and men were 21% more likely than women to undergo reoperation within 90 days (OR 1.21, 1.18 to 1.23; P < 0.001).

conclusionWomen were much more likely than men to undergo cancer surgery than men, but the likelihood of surgery decreased with advancing age and with increasing number of co-morbid conditions, especially in women. These findings highlight a need for both increased awareness and strategies to ensure gender equality in access to oncological surgical treatment and improved outcomes.

Indexed as

NeoplasmsAdultAgedAged, 80 and overFemaleFranceHumansMaleMiddle AgedPostoperative ComplicationsReoperationSex Factors

Identifiers

PMID39150046
PMCPMC11327872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.